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ABSTRACT 
Human fetoplacental vascular function is altered in several pathologies of pregnancy as a 
result of endothelial dysfunction. Pregnancy is a physiological condition coursing with 
increased circulating plasma levels of cholesterol in the mother, to respond to the higher 
demands from the growing fetus. An abnormal increase in maternal plasma cholesterol 
configures a pathological state referred as maternal supraphysiological 
hypercholesterolemia (MSPH). In MSPH, L-arginine transport and synthesis of nitric oxide 
(i.e., L-arginine/NO signalling pathway) as well as arginases/urea cycle in the fetoplacental 
endothelium are altered. Equally, an increase in the physiological gain of weight in 
pregnant women could end with obese women at the end of pregnancy leading to a 
condition referred as obesity in pregnancy (OP). OP seems to be also associated with 
alterations in the L-arginine/NO signalling pathway in endothelium in animal models; 
however, nothing is known regarding alterations of the human fetoplacental endothelium in 
OP. Insulin, adenosine and NO are vasodilators in the fetoplacental vascular bed, and a 
role for these molecules is proposed in MSPH and OP. Alternatively, involvement of 
intracellular pH modulation and the potential involvement of adenosine receptors is 
proposed as phenomena that could improve endothelial dysfunction associated with these 
diseases of pregnancy. 
 











Original received: July 22, 2014; revision received, September 16, 2014; accepted, 
September 22, 2014 
Physiological Mini Reviews, Vol.7 Nº 5, 2014                           
61 
 
MATERNAL HYPERCHOLESTEROLEMIA IN PREGNANCY 
 
Maternal supraphysiological hypercholesterolemia 
 
Pregnancy is a physiological condition characterized by a progressive, weeks of gestation-
dependent increase (reaching 40-50%) of cholesterol and triglycerides in the maternal 
blood [1]. The normal increase of total cholesterol (TCh) during pregnancy is known as 
‘maternal physiological hypercholesterolemia in pregnancy’ (MPH), and is considered to 
be an adaptive response of the mother to satisfy the high cholesterol demand by the 
growing fetus for cell membrane and hormone synthesis, among other functions [1, 2]. 
However, when pregnancy-associated hypercholesterolemia goes over this physiological 
adaptation a different condition is identified, i.e., maternal supraphysiological 
hypercholesterolemia (hereafter referred as ‘MSPH’) [1-3].  
Maternal TCh is transported through the placenta to the fetal circulation [4]. A strong 
correlation between maternal cholesterolaemia during pregnancy and the size of 
atherosclerotic lesions in arteries of neonates and children has been established [5, 6]. 
Additionally, MSPH leads to human placental vascular dysfunction, a phenomenon 
associated with reduced synthesis of the vasodilator nitric oxide (NO) [2, 3]. The effects of 
MSPH in the fetal vasculature could affect the initiation and progression of fetal 
atherosclerosis and may influence the molecular memory of the vasculature in response to 
future risk factors, a phenomenon recognized as in utero programming, which occurs 
during a limited prenatal period and leads to permanent changes [7].  
 
 
Cut-off point for MSPH in pregnancy  
 
There are no clinical reference values established for total and lipoprotein cholesterol 
levels during pregnancy in the global pregnant population [1-3]. In a Chilean population of 
pregnant women the mean of TCh at term of pregnancy was estimated in 260 mg/dL [2, 3]. 
This value is similar to reports in the literature showing ~246 mg/dL for TCh at term [3, 8] 
and comparable with values for TCh in pregnant population from Argentina (~244 mg/dL), 
Brazil (~243 mg/dL) and Colombia (~269 md/dL) [3].  
MSPH is a maternal condition defined by considering a cut-off point for TCh at term of 
pregnancy of ~280-300 mg/dL, which associates with vascular alterations at birth and even 
in the childhood [2]. Increased oxidative stress in the maternal and fetal blood and the 
placenta [9], as well as reduced expression of the placental low-density lipoprotein (LDL) 
receptor [10] in pregnancies coursing with maternal TCh levels over this value are 
described. Moreover, increased early atherosclerotic markers, such as fatty streaks and 
lipid peroxidation, were determined in human fetal aorta [5] and in 7- to 14-year-old 
children aortas [6] born from mothers coursing with MSPH. Furthermore, endothelial 
dysfunction in the human umbilical vein from pregnancies coursing with values of TCh 
over this cut-off point exhibit reduced NO synthesis and endothelium-dependent vascular 
relaxation [2, 3]. Interestingly, ~30% of the pregnant women that were included in the 
study developed MSPH during pregnancy associated with increased levels of LDL 
cholesterol (LDL-Ch) [2]. Thus, maternal LDLs could be the lipoproteins mainly involved 
in the vascular effects of MSPH in the fetal circulation. Furthermore, a significantly higher 
number of pregnant women will potentially present an adverse intrauterine condition 
leading to the development of vascular alterations as endothelial dysfunction and early 
atherosclerosis in the growing fetus. 
 





NO and MSPH 
 
MSPH modifies at least two cellular pathways related with the endothelial function of the 
fetoplacental vasculature, i.e., the L-arginine/NO signalling pathway and the arginases/urea 
cycle [2, 3]. Pregnant women with MSPH show altered umbilical vein reactivity and 
umbilical vein endothelial dysfunction at birth compared with MPH. Although the 
maternal levels of TCh and LDL-Ch were increased in the MSPH group, the newborns 
from this group of women exhibit normal levels of TCh, HDL-Ch and triglycerides [2]. 
This finding suggests that a regulation in the traffic of cholesterol (i.e., transport of 
cholesterol from the maternal circulation to the placenta and efflux of cholesterol from the 
placenta to the fetal circulation) is occurring in the placenta [4]. MSPH is associated with 
reduced calcitonin gene related peptide dilation of umbilical vein rings an endothelium-
derived NO dilation of the placental vasculature [2]. The reduced NO synthesis detected in 
HUVECs from MSPH compared with MPH, was paralleled by reduced Serine1179 
phosphorylation (phosphorylation associated with eNOS activation), but unaltered total 
eNOS protein abundance [2]. MSPH was also associated with increased activity of 
arginases and increased protein abundance of arginase II (ARG II), an enzyme that 
competes with eNOS for the substrate L-arginine [11]. Interestingly, arginases activity 
inhibition partially reverses MSPH effect on vein ring dilation. Thus, MSPH results in 
human umbilical vein endothelial dysfunction likely due to an imbalance between eNOS 
and ARGII activity and expression [2, 3] (Figure 1).  
 
 
Figure 1. Role of insulin and adenosine on NO availability in MSPH. MSPH associates with increased (ñ) 
L-arginine transport in HUVECs compared with cells from MPH. This phenomenon is mainly due to higher 
transport capacity via the human cationic amino acid transporters 1 (hCAT-1) in this cell type. The increased 
L-arginine transport results in higher bioavailability of this amino acid in the intracellular space for its 
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catabolism via endothelial nitric oxide synthase (eNOS) and arginase II. L-Arginine is preferentially used by 
arginase II (solid blue arrow) compared with eNOS (dotted arrow), resulting in a reduced (ò) synthesis of 
nitric oxide (NO), characteristic of endothelial dysfunction in MSPH. The potential contribution of insulin 
and adenosine signalling in this phenomenon in MSPH is unknown (?). However, since insulin via insulin 
receptors (IRs) activation does not alter L-arginine transport or NO synthesis in HUVECs from MSPH (A 
Leiva, L Sobrevia, unpublished), abnormal signalling following IRs activation probably due to altered level 
of cholesterol in the plasma membrane is proposed. Although the expression of adenosine receptors (ARs) 
may be altered in MSPH, the involvement of ARs in the genesis of MSPH is unknown as well as the 
contribution of their cell signalling mechanisms in NO metabolism. Considering that insulin and adenosine 
are potent vasodilators [2, 3, 12, 19], further studies are needed to characterize the potential cell mechanisms 
associated with NO synthesis in the fetoplacental vascular bed in MSPH.  
 
 
Insulin and MSPH  
 
Another molecule potentially modulated in MSPH is the hormone insulin, a key hormone 
for the placental metabolic regulation that is required in a normal pregnancy [12]. In the 
fetoplacental vasculature the insulin receptors (IRs) types A (IR-A) and B (IR-B) are 
expressed and are differentially regulated in the macrocirculation [13, 14] and in the 
microcirculation [15]. IRs are located in caveolae, a micro domain of the plasma 
membrane enriched in the protein caveolin [16], which is modified by plasma membrane 
cholesterol distribution [17]. Since high level of TCh increases the expression of caveolin 
and alters the caveolae structure modulating the activity of proteins located in caveolae 
such as eNOS [17], alterations in insulin signalling in pregnancies coursing with MSPH is 
feasible. Preliminary findings from our group show that MSPH associates with reduced 
vasodilatation of human umbilical vein rings in response to insulin (Leiva A, Sobrevia L, 
unpublished), a phenomenon that could be mediated by endothelial dysfunction since NO 
synthesis is also altered in HUVECs from these patients [3, 2]. 
 
 
Adenosine and MSPH 
 
Adenosine is an endogenous purine nucleoside that maintains the homeostatic equilibrium 
via activation of adenosine receptors (ARs) [18]. Adenosine biological effects include 
modulation of energy homeostasis (ATP metabolism) and regulation of vascular tone [12, 
13, 18, 19]. Interestingly, ARs have a significant role in the regulation of the cholesterol 
levels and atherosclerosis. Endothelial cells of mice lacking the A2B adenosine receptors 
(A2BAR) have increased levels of adhesion molecules and pro-inflammatory cytokines, 
promoting endothelial dysfunction and a pro-atherogenic profile [20]. Indeed, deficiency of 
A2BAR leads to increased atherosclerosis lesions in mice; a phenomenon associated with 
higher plasma TCh (predominantly very low-density lipoprotein (vLDL-Ch)) and 
triglycerides. Additionally, administration of A2BAR specific agonist in control mice leads 
to a reduction in lesion formation, and lower plasma lipids level [21]. Null-mice for 
A2AAR have elevated levels of plasma TCh (predominantly low-density lipoprotein (LDL-
Ch)) and pro-inflammatory markers [22]. Pharmacological activation of A2AAR in 
endothelial cells from human aorta associates with increased efflux of cholesterol from the 
cells, a phenomenon mainly due to up-regulation of the ATP-binding cassette (ABC), sub-
family A, member 1 (ABCA1) and ABC, sub-family G, member 1 (ABCG1) transporters 
[23]. In addition, A3AR deficiency does not alter plasma TCh or atherosclerosis 
development [24]. Altogether, this evidence strongly suggests that ARs are involved in the 
regulation of cholesterol levels and in the development of atherosclerosis. However, 
whether these receptors are involved in the genesis of MSPH or whether plasma levels of 
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adenosine are altered in MSPH is unknown. Interestingly, pregnancies coursing with 
gestational diabetes mellitus (GDM) associates with increased plasma adenosine 
concentration in the umbilical blood with subsequent alterations of endothelial cell 
function [13-15]. In some cases women coursing with GDM also develop maternal 
hypercholesterolemia [3]; however a functional link between adenosine metabolism and 
the plasma lipid level has been neglected. Additionally, expression of ARs is altered in 
HUVECs from in GDM (Guzmán-Gutiérrez E, Sobrevia L, unpublished), but the potential 
consequences of these alterations on the cholesterol metabolism are unknown. 
 
 
MATERNAL OBESITY IN PREGNANCY 
 
Maternal gain of weight in pregnancy  
 
Obesity is a worldwide disease that presents a risk to health defined in a patient with a 
body mass index (BMI) ≥30 kg/m2 [25]. The incidence of obesity is currently ~12% at 
worldwide and is certainly increasing. According with WHO reports ~14% of women in 
the world suffer obesity [25], of which ~29% are in their reproductive age [26]. Thus, 
obesity during pregnancy is a critical condition for pregnancy management since it is in 
most cases preventable. When women with normal BMI (range 18.5 – 24.9 kg/m2) [25] at 
the beginning of pregnancy exhibit a supraphysiological gain of weight reaching BMI ≥30 
result in a condition defined as obesity during pregnancy (OP). While obesity is a 
condition that courses with systemic metabolic misbalance leading to multiple 
complications including endothelial dysfunction, the impact of OP on fetal endothelial 
function remains unknown [19]. 
In pregnancies coursing with maternal obesity increased risk of fetal mortality and 
morbidity, congenital malformations, macrosomia and increased incidence of caesarean 
delivery is reported [27]. However, whether this condition is due to OP or to pregestational 
obesity is unfortunately unknown since most of these studies do not separate this group of 
patients from normal, overweight (BMI = 25.0 – 29.9) or obese patients. Additionally, an 
inflammatory profile in the placenta from obese women has been described [28]; however, 
the consequences of OP on fetoplacental vasculature function, including expression and 
function of the endothelial L-arginine/NO signalling pathway, remain unknown [19, 28].  
 
Cut-off point for OP in pregnancy 
 
The effect of OP on human fetal endothelium is unknown, with only some studies in the 
aorta in an obese murine model [29]. In addition to the need of knowing the mechanism(s) 
that are altered by OP leading to endothelial dysfunction, a cut-off point value for OP is 
required. During pregnancy, several guidelines propose a potential physiological (i.e., 
normal) gain of weight based on pre-gestational weight of the women. At least two 
different guidelines characterizing Chilean pregnant women have been proposed [30, 31]. 
Based on preliminary observations fetoplacental vascular dysfunction has been found in 
HUVECs from women exhibiting BMI >30 classified as obese at term under Mardones & 
Rosso’s report [31] or overweight and obese under Atalah et al’s report [30] for Chilean 
population. Indeed, in pregnancies cursing with OP (i.e., BMI >30) the correlation between 
newborn weight and gestational age is lost (Pearson correlation, r = 0.36, p<0.01 for 
normal pregnancies compared with r = 0.13, p = 0.5253 for OP) (Figure 2), suggesting that 
this condition is critical and could result in altered fetal outcome. At present, the 
characteristics of foetal endothelial function in OP are not defined, even when there is 
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information regarding endothelium-dependent modulation of vascular homeostasis by NO, 
adenosine or insulin. 
 
 
Figure 2. Correlations between newborn weight and gestational age. Pearson correlation for newborn weight 
and gestational age at term in pregnancies where maternal gain of weight ended within a normal (Normal) 
body mass index (BMI = 18.5 – 24.9 kg/m2) or in obesity (OP) (BMI >30 kg/m2). 
 
 
NO and OP 
 
Control mechanisms of NO synthesis in endothelial cells, such as eNOS activation or 
deactivation by phosphorylation, protein association and cellular localization, among 
others, are well known [32]. eNOS associates to caveolin 1 leading to reduce NO 
synthesis, which is even more attenuated when caveolin-1 is overexpressed [32, 33]. 
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However, even knowing that HUVECs express caveolin, nothing is reported regarding OP 
and NO synthesis. As expected, an increase in caveolin-1/eNOS association would lead to 
lower NO synthesis in the human fetoplacental endothelial cells from normal pregnancies 
[19]. The latter findings and eNOS expression in OP is not documented. However, lower 
eNOS protein abundance an NO synthesis is reported in human subcutaneous fat arterioles 
endothelium from obese patients [34]. Furthermore, increased caveolin-1 expression while 
eNOS expression remains unaltered in saphenous arteries is reported [35]. Thus, both 
increase in caveolin-1 and/or decrease in eNOS could be potential mechanisms leading to 
lower NO bioavailability in the fetoplacental vasculature in OP in humans [19]. 
 
Insulin and OP 
 
It is known that pregnancy is a condition that courses with a physiological state addressed 
as low sensitivity to insulin [13-15, 19]. In other metabolic alterations during pregnancy, 
such as in GDM, insulin restores macrovascular and microvascular endothelial dysfunction 
[13-15, 19] via a mechanism including differential activation of IR-A and IR-B, as well as 
ARs [13, 14]. However, the involvement of these IRs and the potential requirements of 
ARs for its biological effects in OP are not available. Pregnant obese women exhibit 
increased fasting insulin compared to pregnant non-obese women [36]; however, the effect 
of this hyperinsulinemia in the placental endothelial function in normal pregnancies as well 
as in OP remains unknown [19]. 
 
Adenosine and OP 
 
Obesity associates with altered human fetoplacental vascular function, and a relationship 
between ARs and adipogenesis in adipocytes is reported [37], there are not studies 
addressing the potential role of ARs and/or activity and expression of the human 
equilibrative nucleoside transporters (hENTs) in the fetoplacental endothelial cell function 
in OP [19]. hENTs are expressed in HUVECs [13, 14] and human placental microvascular 
endothelial cells (hPMECs) [15] and play crucial roles in the uptake of adenosine 
maintaining physiological extracellular levels of this vasodilator [13, 19]. In addition, a 
potential direct or indirect effect of ARs activation on NO level, as proposed to occur in 
pathologies of pregnancy such as GDM [13-15] or PE (Salsoso R, Sobrevia L, 
unpublished), has not been investigated in OP [13, 19]. Interestingly, the transcription 
factors complex CCAAT/enhancer binding protein (C/EBP) homologous protein 10 
(hCHOP)-C/EBPα (hCHOP-C/EBPα), which down-regulates SLC29A1 (encoding for 
hENT isoform 1 (hENT1)) expression in HUVECs [13], is also expressed in human 
adipocytes where causes down-regulation of SCL2A4 (encoding for glucose transporter 
isoform 4 (GLUT4)) expression [38]. In addition, obesity is also associated with altered 
insulin signalling in several tissues, and activates mitogen-activated protein kinases 
(MAPK) signalling cascades enhancing insulin resistance [13], but nothing is known 
regarding the effect of OP in these signalling mechanisms in the fetoplacental vascular 
endothelium.  
 
INTRACELLULAR pH IN PREGNANCY 
 
Intracellular pH regulation and endothelial function 
 
As a normal consequence of cellular metabolism mammalian cells generate H+. Different 
membrane transport systems maintain a stable intracellular pH (pHi) value of ~7.2 with an 
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extracellular pH (pHo) of ~7.4 [39]. If the expression and/or activity of the membrane 
transport systems maintaining these pH values are altered, cellular processes are deeply 
affected compromising cell viability. Thus, the control of pHi and pHo is critical for an 
adequate cellular function. Extrusion of H+ occurs via Na+/HCO3- co-transporter (NBCn1) 
and Na+/H+ exchanger isoform 1 (NHE1), a member of NHEs family, in arterial vascular 
smooth muscle and endothelium [39]. Normal function of these membrane transport 
systems is critical for controlling pHi, with NHE1 mainly accounting for H+ extrusion in 
low pHi conditions (i.e., acidic) compared with non-acidic pHi [39]. The 
syncytiotrophoblast, which is in contact with both maternal and fetal vasculature, is 
responsible of H+ transfer from the fetal to the maternal circulation. In this cell type, the 
recovery of pHi after an acid-pulse depends on NHEs activity [40]. In addition, NHE1 and 
NHE2 mRNA are detected during the pregnancy, of which NHE2 mRNA level is higher in 
the last weeks of gestation [41]. Importantly, NHEs expression in the syncytiotrophoblast 
is reduced in preterm and in growth restricted placentas, suggesting that modulation of 
NHE expression may play a role in diseases of pregnancy [42]. 
Inhibition of NHEs function is regarded as a condition leading to vasodilation via eNOS 
[43]. The relaxation caused by cariporide (NHEs inhibitor) in rat aorta is reduced in eNOS 
deficient-mice and after treatment with the NOS inhibitor NG-nitro-L-arginine methyl ester 
(L-NAME). Mechanistically, cariporide reduces pHi leading to release of intracellular Ca2+ 
from the endoplasmic-reticulum stores in bovine aortic endothelial cells. This increase in 
Ca2+ level allows association between eNOS and calmodulin increasing NO synthesis [43]. 
Additionally, hyperglycaemia, a condition exhibited in patients with diabetes mellitus or 
obesity, associates with endothelial dysfunction [12, 19, 44]. It is reported that this adverse 
environmental condition decreases NO production by reducing eNOS activity. Under these 
conditions, NHE1 and the Ca2+-dependent protease calpain are activated, resulting in the 
dissociation of eNOS from the heat-shock protein 90 (Hsp90) and its subsequent 
inactivation. Inhibition of NHE1 by cariporide or in HUVECs knockdown for NHE1 
results in lower pHi value and restoration of eNOS activity [44]. 
NHE1 activation appears to be also involved in several steps of atherosclerosis, including 
NHE1-mediated adherence of leukocytes to endothelial cells [45]. NHE1 activity is 
decreased by LDL-Ch, but increased by HDL-Ch in human platelets. Thus, the use of 
NHE1-inhibitors is proposed as a potential therapy for atherogenesis [45]. Rabbits 
subjected to an atherogenic diet exhibit cholesterol-dependent endothelial dysfunction, and 
treatment with cariporide recovers these alterations improving cholesterol level [46]. These 
findings indicate that targeting NHE1 could be a promising alternative to recovers 
endothelial function in diseases of pregnancy (Figure 3). However, whether the 
endothelial dysfunction observed in pathologies of pregnancy regards NHE1 activity 




MSPH and OP are diseases of pregnancy, which could course with detrimental effects on 
the fetoplacental vascular and endothelial function. In the absence of a cut-off value for the 
MSPH it was recently suggested that maternal total cholesterol over 280 mg/dL associates 
with altered fetoplacental endothelial L-arginine/NO signalling pathway and vascular 
reactivity [2, 3]. A cut-off value for OP is not reported, including for Chilean population. 
However, it is suggested that a BMI >29 kg/m2 (Atalah’s chart) [30] or >30 kg/m2 
(Mardones & Rosso’s chart) [31] could be considered as a cut-off value for OP leading to 
altered human fetoplacental dysfunction (Figure 4). These pathological conditions could 
result from altered endothelial function due to abnormal regulation of the pHi with a 
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critical role played by NHE1 for H+ extrusion. Insulin, adenosine and NO vascular effects 
could associates with NHE1 expression and activity. In addition, adenosine receptors in 








Figure 3. Proposed model for a potential role of NHE1 in human fetoplacental endothelial dysfunction. In 
non-pathological conditions the Na+/H+ exchanger 1 (NHE1) expression and/or activity remain in a 
physiological level, thus, maintaining a normal intracellular pH (pHi). Under pathological conditions such as 
maternal supraphysiological hypercholesterolemia (MSPH) or maternal gain of weight ending in obesity in 
pregnancy (OP), NHE1 expression and/or activity may increase (ñ), leading intracellular alkalization 
(increased (ñ) pHi value) involving transcriptional and/or post-translational mechanisms. Increased NHE1 
expression and/or activity will result in inhibition of endothelial nitric oxide synthase (eNOS) activity, hence 
reducing nitric oxide (NO) synthesis leading to reduced vasorelaxation. In addition, NHE1 and increase in 
the pHi could result in deleterous effects decreasing insulin activation (+) of eNOS, thus contributing to 
MSPH and OP-mediated endothelial dysfunction in the fetoplancental vasculature. We envisage the 
possibility of future studies aiming to explore whether NHE1 inhibitors could result in improving fetal 
endothelial function in this diseases in human pregnancy. 
 






Figure 4. Proposed cut-off values for human fetoplacental endothelial dysfunction. In pregnant women 
coursing with maternal supraphysiological hypercholesterolemia (MSPH) the level of maternal plasma total 
cholesterol from and over 280 mg/dL associates with manifestation of human fetoplacental endothelial 
dysfunction (green area) [2, 3]. In pregnancies where the maternal gain of weight result in obesity in 
pregnancy (OP) a maternal body mass index (BMI) at term from and over 29 kg/m2 associates with human 
fetoplacental endothelial dysfunction (orange area) (Pardo F, Sobrevia L, unpublished). 
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